10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018
Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Changes in COPD symptom control questionnaire (CCQ) scores after seven days of treatment with prednisolone of acute exacerbations in hospitalised patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 54s Year: 2003
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Is the asthma control questionnaire (ACQ) usefull during acute moderate to severe (AMS) asthma exacerbations (AE)? Source: Eur Respir J 2004; 24: Suppl. 48, 591s Year: 2004
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013
Asthma symptoms, SABA use, and lung function before and after a moderate or severe exacerbation Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016
Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007
Intranasal budesonide improves quality of life in patient with COPD and chronic nasal symptoms Source: International Congress 2016 – COPD diagnosis and management Year: 2016
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
The effect of treatment duration by inhaled glucocorticosteroids, on “cough variant asthma” in children Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013